Cargando…
What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection?
BACKGROUND: Schistosomiasis is endemic in 54 countries, but has one of the lowest coverages by mass drug administration of all helminth diseases. However, with increasing drug availability through donation, the World Health Organisation has set a goal of increasing coverage to 75 % of at-risk childr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618750/ https://www.ncbi.nlm.nih.gov/pubmed/26489831 http://dx.doi.org/10.1186/s13071-015-1157-y |
_version_ | 1782396971228594176 |
---|---|
author | Anderson, RM Turner, HC Farrell, SH Yang, Jie Truscott, JE |
author_facet | Anderson, RM Turner, HC Farrell, SH Yang, Jie Truscott, JE |
author_sort | Anderson, RM |
collection | PubMed |
description | BACKGROUND: Schistosomiasis is endemic in 54 countries, but has one of the lowest coverages by mass drug administration of all helminth diseases. However, with increasing drug availability through donation, the World Health Organisation has set a goal of increasing coverage to 75 % of at-risk children in endemic countries and elimination in some regions. In this paper, we assess the impact on schistosomiasis of the WHO goals in terms of control and elimination. METHODS: We use an age-structured deterministic model of schistosome transmission in a human community and the effect of mass drug administration. The model is fitted to baseline data from a longitudinal re-infection study in Kenya and validated against the subsequent re-infection data. We examine the impact on host worm burden of the current treatment trend, extrapolated to meet the WHO goals, and its sensitivity to uncertainty in important parameters. We assess the feasibility of achieving elimination. RESULTS: Model results show that the current treatment trend, extrapolated to the WHO goals, is able to greatly reduce host worm burdens. If coverage is continued at the same level beyond 2020, elimination is possible for low to moderate transmission settings, where transmission intensity is defined by the basic reproduction number, R(0). Low levels of adult coverage have a significant impact on worm burden in all settings. Model validation against the re-infection survey demonstrates that the age-structured model is able to match post-treatment data well in terms of egg output, but that some details of re-infection among school children and young adults are not currently well represented. CONCLUSIONS: Our work suggests that the current WHO treatment goals should be successful in bringing about a major reduction in schistosome infection in treated communities. If continued over a 15 year period, they are likely to result in elimination, at least in areas with lower transmission. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-015-1157-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4618750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46187502015-10-25 What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection? Anderson, RM Turner, HC Farrell, SH Yang, Jie Truscott, JE Parasit Vectors Research BACKGROUND: Schistosomiasis is endemic in 54 countries, but has one of the lowest coverages by mass drug administration of all helminth diseases. However, with increasing drug availability through donation, the World Health Organisation has set a goal of increasing coverage to 75 % of at-risk children in endemic countries and elimination in some regions. In this paper, we assess the impact on schistosomiasis of the WHO goals in terms of control and elimination. METHODS: We use an age-structured deterministic model of schistosome transmission in a human community and the effect of mass drug administration. The model is fitted to baseline data from a longitudinal re-infection study in Kenya and validated against the subsequent re-infection data. We examine the impact on host worm burden of the current treatment trend, extrapolated to meet the WHO goals, and its sensitivity to uncertainty in important parameters. We assess the feasibility of achieving elimination. RESULTS: Model results show that the current treatment trend, extrapolated to the WHO goals, is able to greatly reduce host worm burdens. If coverage is continued at the same level beyond 2020, elimination is possible for low to moderate transmission settings, where transmission intensity is defined by the basic reproduction number, R(0). Low levels of adult coverage have a significant impact on worm burden in all settings. Model validation against the re-infection survey demonstrates that the age-structured model is able to match post-treatment data well in terms of egg output, but that some details of re-infection among school children and young adults are not currently well represented. CONCLUSIONS: Our work suggests that the current WHO treatment goals should be successful in bringing about a major reduction in schistosome infection in treated communities. If continued over a 15 year period, they are likely to result in elimination, at least in areas with lower transmission. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13071-015-1157-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-22 /pmc/articles/PMC4618750/ /pubmed/26489831 http://dx.doi.org/10.1186/s13071-015-1157-y Text en © Anderson et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Anderson, RM Turner, HC Farrell, SH Yang, Jie Truscott, JE What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection? |
title | What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection? |
title_full | What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection? |
title_fullStr | What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection? |
title_full_unstemmed | What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection? |
title_short | What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection? |
title_sort | what is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618750/ https://www.ncbi.nlm.nih.gov/pubmed/26489831 http://dx.doi.org/10.1186/s13071-015-1157-y |
work_keys_str_mv | AT andersonrm whatisrequiredintermsofmassdrugadministrationtointerruptthetransmissionofschistosomeparasitesinregionsofendemicinfection AT turnerhc whatisrequiredintermsofmassdrugadministrationtointerruptthetransmissionofschistosomeparasitesinregionsofendemicinfection AT farrellsh whatisrequiredintermsofmassdrugadministrationtointerruptthetransmissionofschistosomeparasitesinregionsofendemicinfection AT yangjie whatisrequiredintermsofmassdrugadministrationtointerruptthetransmissionofschistosomeparasitesinregionsofendemicinfection AT truscottje whatisrequiredintermsofmassdrugadministrationtointerruptthetransmissionofschistosomeparasitesinregionsofendemicinfection |